In their response, Ostrovsky et al. 1 suggest the lack of concordance between their findings and our findings may reflect differences between the populations studied. As stated by Ostrovsky et al.,
1 their patient and control populations were heterogeneous, including individuals from several Jewish and non-Jewish ethnic groups. In contrast, all of the patient and control individuals included in our study 2 were of Northern Irish origin. Due to its geographical isolation and historically low levels of inward migration, the population of Northern Ireland may be considered to be genetically more homogeneous relative to other populations, such as the Israeli population, studied by Ostrovosky et al. As such, we suggest that the influence of genetic factors predisposing to complex conditions, such as ALL, may be more apparent in our population.
The different allele frequencies of the Arg307Lys SNP reported for healthy control populations in the two studies by Ostrovosky et al.
3,4 require further explanation. Ostrovsky et al.
1
suggest that these differences are related to the ethnic composition of the control populations recruited. Their initial study, 3 included healthy individuals from four Israeli Jewish populations (Ashkenazi, North African, Mediterranean and Near Eastern). The allele frequencies for the Arg307Lys SNP were similar in each of these populations and comparable to our data for healthy individuals in the Northern Ireland population (Arg/ Lys; 74.44/25.56%) 2 and to allele frequencies for European populations listed on the NCBI SNP database. 5 In their subsequent study, 4 Ostrovsky et al. 1 point out that the healthy control group included the four Israeli Jewish populations mentioned above plus individuals from other Jewish and nonJewish populations. In this study, the allele frequency reported was substantially different (Arg/Lys; 83.49/16.51%). 4 Ostrovsky et al. do not provide information on the ethnic breakdown of this group but their results suggest a very different allele frequency in the additional Jewish and non-Jewish populations included in this study.
In conclusion, we consider that a degree of uncertainty remains concerning the frequency of the Arg307Lys SNP in the population studied by Ostrovosky et al. 4 Furthermore, we suggest that the relative genetic homogeneity of the Northern Ireland population included in our study lends weight to our findings.
Reply to Winter et al. The lack of the results of replication 1, 2 in different studies is a very complicated problem. Recently, this question regarding gene-disease association studies was analyzed by Moonesinghe et al. 3 Nonreplication may be the result of population stratification, phenotype misclassification, genotyping error, selection biases and differences in genetic effects that include differential linkage disequilibrium of the identified genetic markers with culprit gene variant, population-specific genegene or gene-environment interactions. 3 The authors represent methods for estimating the required sample size to replicate an association across studies with different amounts of between-study heterogeneity. The simulations conducted by Moonesinghe et al. 3 show that some true associations may be nonreplicable, since the power to replicate the associations may remain below a given level, regardless of how large study populations may be included in the replication efforts. Their calculations suggest that a sample size that exceeds 40 000 subjects or even larger is absolutely essential in the case of modest effect size and between-study heterogeneity.
Hence, it is very difficult to compare our two HPSE gene association studies 1, 4 that were performed on small sample-size groups from different populations. Moreover, the HPSE gene has complicated structure of single-nucleotide polymorphism (SNP) blocks. 5 This fact requires the characterization of HPSE gene SNPs in the studied populations, using more than one SNP and the construction of haplotypes, which may confirm or reject suggested correlation.
Our study 4 represents association between HPSE gene SNPs and acute lymphoblastic leukemia, which were found in Israeli population. Future tasks are to detect and investigate the role of functional SNPs in normal and pathological processes, in which heparanase is involved, and clarify the function of the HPSE gene in acute lymphoblastic leukemia pathogenesis. We appreciated Dr Bergsagel's thoughtful editorial 1 accompanying our paper on the long-term survival of patients in whom metaphase cytogenetic abnormalities were effectively suppressed. 2 We wish to put that work in the context of almost 20 years of clinical trial and translational research in multiple myeloma at the University of Arkansas for Medical Sciences.
When we introduced stem cell-supported high-dose melphalan as a therapeutic strategy for myeloma in the 1980s, we had 
Figure 1
Clinical outcomes of patients treated with total therapies (TT1, TT2 and TT3). Given are Kaplan-Meier plots of patients treated with TT1 (gold), TT2 without thalidomide (green), TT2 with thalidomide (red) and TT3 (blue). The four panels depict overall survival (top left), event-free survival (top right), time to stringently defined complete remission (s-CR; bottom left) and duration of s-CR from its onset (bottom right). The progressive improvement in the four clinical end points is readily appreciated with the transition from TT1 to TT2 to TT3. The plateau in the CR duration curve for TT1 from 10 years onward (bottom right panel, gold) is consistent with cure.
